Physician profile
Robin Brown
NPI 1134773922
$2,369.63
in general payments reported to CMS, 2019-2025
23 companies · $661 in 2025
The $661 reported for 2025 was more than what 78% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.56 · 2022: $277 · 2023: $756 · 2024: $661 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.44 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.58 | 2022-2025 | |
| Lilly USA, LLC | $258.87 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $162.42 | 2022-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $145.27 | 2024-2025 | Veozah |
| Pfizer INC. | $132.59 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $125.73 | 2024 | Gemtesa |
| Glaxosmithkline, LLC. | $122.17 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $96.59 | 2023-2025 | Otezla, Repatha, Repatha |
| Hologic Sales and Service, LLC | $94.55 | 2025 | Aptima |
| Exact Sciences Corporation | $74.07 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $71.46 | 2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $70.81 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $69.91 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.78 | 2023-2024 | Xifaxan, Trulance |
| Optinose US, INC. | $59.02 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $56.57 | 2023-2024 | Breztri |
| Esperion Therapeutics, INC. | $52.65 | 2021-2023 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $39.45 | 2023-2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $20.80 | 2025 | Gvoke Hypopen |
| Verona Pharma, INC. | $18.03 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $15.94 | 2023 | |
| Mylan Specialty L.P. | $15.81 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $15.56 | 2025 | Capvaxive, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.